Healio’s top FDA articles in ophthalmology for 2024 included updates on the approval of various treatments. This included the FDA clearing the Faros anterior cataract surgery system, approving the Vabysmo prefilled syringe for retinal diseases, and approving aflibercept biosimilars Yesafili and Opuviz. Additionally, the FDA granted rare pediatric disease and fast track designations to gildeuretinol, an oral therapy for Stargardt disease. The FDA also granted de novo classification to the Fysx ocular pressure adjusting pump. These developments mark significant advancements in ophthalmic treatments and therapies in 2024.
Source link
Top items in ophthalmology for 2024
